The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
Missouri $ 7,695,336.79
| Applicant Name |
Project Name |
Grants Awarded for 2009 |
Grants Awarded for 2010 |
| Antigen Laboratories, Inc |
Sublingual CAT Hair Allergenic Extract |
$ 244,479.25 |
|
| APT Therapeutics, Inc. |
Therapeutic Use of Human Apyrase |
$ 244,479.25 |
|
| BioMed Valley Discoveries Inc |
Combination Bacteriolytic Therapy {COLBALT} Project |
$ 6,403.00 |
$ 178,957.50 |
| BioMed Valley Discoveries, Inc |
Phenix Inflammation Project |
$ 244,479.25 |
|
| BioMed Valley Discoveries, Inc. |
In Vivo FIAU Project |
$ 69,601.00 |
$ 174,878.25 |
| BioMed Valley Discoveries, Inc. |
Phenix Chagas Project |
$ 43,688.50 |
$ 72,998.00 |
| BioMed Valley Discoveries, Inc. |
Phenix Diabetes Project |
$ 116,561.50 |
$ 127,917.75 |
| CardiaLen, Inc. |
Low-Energy Atrial Cardioverter |
$ 42,532.00 |
$ 188,481.00 |
| Daya Drug Discoveries Inc |
Novel Serotonin Agonists/Antagonists for the Treatment of Neurological Disorders |
$ 83,759.00 |
$ 102,600.00 |
| Daya Drug Discoveries Inc |
Small Molecule Steriod Mimics for Molecular Imaging and Therapy of Breast Cancers |
|
$ 20,000.00 |
| ENDOSTIM INC |
ENDOSTIM MICROSTIMULATOR |
$ 152,091.15 |
$ 92,388.10 |
| Evogen, Inc |
Fully automated point of care platform for the diagnosis of infectious disease and genotyping |
$ 244,479.25 |
|
| Foundation Care LLC |
Cystic Fibrosis Health Management Program |
$ 110,000.00 |
$ 134,479.24 |
| Galera Therapeutics LLC |
Development of a Drug to Prevent Oral Mucositis in Cancer Patients |
|
$ 244,479.25 |
| Gerhard W. Cibis, M.D., P.C. |
Automated Video Vision Development Assessment (AVVDA) |
$ 46,300.50 |
$ 44,000.00 |
| Immunophotonics, Inc |
Laser-Assisted Immunotherapy |
$ 7,821.54 |
$ 236,657.71 |
| ISTO Technologies Inc |
Cell-based technology platform |
$ 244,479.25 |
|
| Kereos, Inc |
Molecularly Targeted Nanostructures for Anticancer Therapy with Cytologic Peptides |
$ 88,108.50 |
$ 66,696.50 |
| Kereos, Inc |
Development of a F-19 Imaging Agent for Early Diagnosis of Cancer and Cardiovascular Disease |
$ 162,045.00 |
$ 82,434.24 |
| LipoSpectrum LLC |
Multi-Dimensional Mass Spectrometry-based Shotgun Lipidomics (MDMS-SL) |
$ 90,860.00 |
$ 95,111.50 |
| Mediomics LLC |
Molecular PINCER-based biosensors for point of care diagnosis |
$ 244,479.24 |
|
| Mobius Therapeutics, LLC |
Optomycin |
$ 230,779.50 |
$ 13,699.74 |
| Pepex Biomedical |
Composite Conductive Monofilament (CCM) Biosensor Technology- Therapeutic Applications |
$ 244,479.25 |
|
| Sequoia Sciences, Inc. |
Novel therapeutic vaccine for urinary tract infections |
$ 159,106.63 |
$ 85,372.61 |
| Sequoia Sciences, Inc. |
Novel Small Molecule Therapeutic for the Treatment of Recalcitrant Bacterial Infections |
$ 244,479.25 |
|
| Shear Kershman Laboratories |
A Tamper Resistant Delivery System for Opiods |
$ 16,408.50 |
$ 95,420.10 |
| Stereotaxis, Inc |
V-Drive |
$ 244,479.25 |
|
| Stereotaxis, Inc |
TOTAR |
$ 40,750.00 |
$ 74,000.00 |
| Stereotaxis, Inc |
STOP-VT |
$ 20,580.00 |
$ 101,804.00 |
| Stereotaxis, Inc. |
Navigant 3.2 |
$ 244,479.25 |
|
| Stereotaxis, Inc. |
Vascular Remote Advancement Systems (VRAS) and Next Gen Radiofrequency Generator |
$ 209,745.50 |
$ 34,733.75 |
| Stereotaxis, Inc. |
Odyssey |
$ 244,479.25 |
|
| Stererotaxis, Inc |
Next Generation Catheters |
$ 120,134.00 |
$ 124,345.25 |
| Traxxsson, LLC |
Biomarkers for Diagnosis and Prognosis of Cancer |
$ 21,947.00 |
$ 41,950.00 |
| Veran Medical Technologies, Inc |
SPiN Drive |
$ 244,479.25 |
|
| VirRx Inc |
Cancer Therapy with Oncolytic Adenovirus VRX-007 |
|
$ 244,479.25 |
| ZeaVision LLC |
Macular Pigment Reflectometer (MPR) |
$ 55,852.50 |
$ 188,626.74 |
References/Related Topics
|
